The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Sonelokimab for psoriatic arthritis: Results from the phase II ARGO trial
|
The phase II ARGO trial (NCT05640245) is assessing the safety and efficacy of sonelokimab, a dual-inhibitor of interleukin (IL)-17A and IL-17F, in patients with active psoriatic arthritis.1 Topline results from this trial were reported previously by the Psoriasis and Psoriatic Arthritis Hub. Week 12 results from this trial were presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress by McInnes.1 |
| Key learnings: |
|
The primary endpoint was met; at Week 12, a greater proportion of patients treated with either sonelokimab 60 mg (n = 41) or 120 mg (n = 43) with induction achieved a 50% improvement in American College of Rheumatology score (ACR50) vs placebo (46.3% and 46.5% vs 20.0%; p < 0.05 and p < 0.01, respectively). |
|
Additionally, at Week 12, more patients treated with sonelokimab achieved an ACR20 and Psoriasis Area and Severity Index 90 response vs placebo; this onset of response was rapid, with improvements observed by Week 4. |
|
Sonelokimab was well tolerated, with no new safety signals. |
| Improvements in patient disease impact scores were observed at Week 12 with sonelokimab vs placebo, depicting an improvement in quality of life with both doses of sonelokimab. |
| Results indicate that sonelokimab is a promising therapy for patients with active psoriatic arthritis and support further phase III trials to assess the potential of this treatment. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
